Literature DB >> 16519834

The relationship between overactive bladder and sexual activity in women.

Ankur S Patel1, Margie L O'Leary, Robert J Stein, Wendy W Leng, Michael B Chancellor, Subodh G Patel, Diane Borello-France.   

Abstract

PURPOSE: We assessed the relationships between bladder symptoms, demographic, and medical history variables and sexual dysfunction in women with overactive bladder (OAB) disorder.
MATERIALS AND METHODS: Seventy-eight women diagnosed with OAB completed self-administered questionnaires related to overall heath status, bladder function, and sexual function. Data were compiled for questionnaire responses, and multivariate logistic regression analyses were performed to determine predictors of sexual dysfunction.
RESULTS: Bothersome bladder symptoms were reported by > or = 60% of the sample. Sixty-percent of the sample was sexually active in the past month. Difficulty with sexual arousal, orgasm, and sexual enjoyment were reported by about 25% of the women. Sexual partner status was the best predictor of sexual arousal, orgasm, and sexual enjoyment. Menopausal status emerged as an important predictor of arousal and sexual enjoyment.
CONCLUSION: The majority of women with symptoms of OAB viewed these symptoms as bothersome. However, the extent of symptom bother did not predict aspects of female sexual dysfunction (FSD). Instead, menopausal and partner status emerged as the best predictors of FSD in our sample.

Entities:  

Mesh:

Year:  2006        PMID: 16519834     DOI: 10.1590/s1677-55382006000100014

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   1.541


  9 in total

1.  The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study.

Authors:  Suleyman Sami Cakir; Recep Burak Degirmentepe; Hasan Anil Atalay; Halil Lutfi Canat; Sait Ozbir; Mehmet Gokhan Culha; Emre Can Polat; Alper Otunctemur
Journal:  Int Urol Nephrol       Date:  2018-11-17       Impact factor: 2.370

2.  Prevalence and correlates of sexual dysfunction among women with bladder pain syndrome/interstitial cystitis.

Authors:  Laura M Bogart; Marika J Suttorp; Marc N Elliott; J Quentin Clemens; Sandra H Berry
Journal:  Urology       Date:  2011-01-07       Impact factor: 2.649

Review 3.  Impact of intravesical onabotulinumtoxinA (Botox) on sexual function in patients with overactive bladder syndrome: a systematic review and meta-analysis.

Authors:  Sami Shawer; Aethele Khunda; Gareth J Waring; Paul Ballard
Journal:  Int Urogynecol J       Date:  2022-01-13       Impact factor: 2.894

Review 4.  Review of current status of female sexual dysfunction evaluation in urogynecology.

Authors:  Ranee Thakar
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-05

Review 5.  Urinary disorders and female sexual function.

Authors:  Jaclyn Chen; Genevieve Sweet; Alan Shindel
Journal:  Curr Urol Rep       Date:  2013-08       Impact factor: 3.092

6.  The assessment of sexual dysfunction in Egyptian women with lower urinary tract symptoms.

Authors:  Gamal El Atrash; Mohamed H Ali; Hassan A Abdelwahab; Lobna A Abdelreheem; Mostafa Shamaa
Journal:  Arab J Urol       Date:  2014-04-28

7.  The effect of extended release tolterodine used for overactive bladder treatment on female sexual function.

Authors:  Athanasios Zachariou; Maria Filiponi
Journal:  Int Braz J Urol       Date:  2017 Jul-Aug       Impact factor: 1.541

8.  The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study.

Authors:  A Zachariou; C Mamoulakis; M Filiponi; F Dimitriadis; J Giannakis; S Skouros; P Tsounapi; A Takenaka; N Sofikitis
Journal:  BMC Urol       Date:  2018-06-25       Impact factor: 2.264

9.  Overactive Bladder during Pregnancy: A Prospective Longitudinal Study.

Authors:  Hung-Ju Chen; Sheng-Mou Hsiao; Cheng-Fang Yang; Chien-Nan Lee; Yi-Wen Wang; Da-Wei Guo; Shiow-Ru Chang
Journal:  Medicina (Kaunas)       Date:  2022-02-06       Impact factor: 2.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.